your market intelligence analyst
Search Results
1,210 results
Your search is now limited to «Immunotherapy» expert search.
In the case of leukaemia drug, pegaspargase (Oncaspar), all five studies examined were considered high risk, while breast cancer drug palbociclib (Ibrance) was approved on the basis of two studies whose results are considered potentially unreliable.
More from Scotland Herald (United Kingdom):
Environmental News Network 09/18/2019 17:21
The researchers say their results suggest that targeting MYH14 and similar cytoskeletal proteins with 4-HAP is a potentially novel strategy for improving the survival of pancreatic cancer patients, and could eventually become part of a combination strategy with chemotherapy and/or immunotherapy agents.
More from Environmental News Network:
We hope this tool may eventually be used to fine tune immunotherapies for individual cancer patients,” Salaita says.
More from Great Things from Small Things . . . Nanotechnology Innovation:
Business Wire 09/18/2019 15:55
Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
More from Business Wire: 09/18/2019 13:41
A major limitation of cancer immunotherapy is that tumors adapt to naturally occurring effector cells by shutting down production of the relevant chemokines in the tumor microenvironment.
More from
This concoction successfully treated patients with sarcoma, carcinoma, lymphoma, melanoma, and myeloma, the scientists wrote.
More from Mail on Sunday (United Kingdom):
ENDPOINTS 09/18/2019 13:10
The emergence of immunotherapy — a ferocious new titan in oncologist’s tool box — takes the breaks off the immune system to kill cancer cells with remarkable success in some cases, but the approach has its own drawbacks.
More from ENDPOINTS:
Immuno-Oncology News 09/18/2019 13:02
We are encouraged to see more than a third of small cell lung cancer patients treated with Imfinzi plus chemotherapy alive at the 18-month landmark, which is remarkable given the aggressive nature of the disease,” José Baselga, executive vice president of oncology research and development at AstraZeneca, said in a news release ...
More from Immuno-Oncology News:
ScienceDaily 09/18/2019 12:45
Recent studies have also investigated CD137 as an attractive target for cancer immunotherapy.
More from ScienceDaily:
Healio News 09/18/2019 12:18
My clinical responsibilities are as a nurse-practitioner for gastrointestinal cancers, so my area of clinical focus is pancreatic and metastatic colorectal cancer.
More from Healio News:
BioPharma Dive 09/18/2019 11:50
Project Orbis, piloted by the FDA's Oncology Center of Excellence, is designed to help coordinate cancer drug reviews, allowing for simultaneous approval and, in theory, earlier patient access to new treatments.
More from BioPharma Dive:
Ovarian Cancer News Today 09/18/2019 11:12
IMV announced that it has joined with the Wistar Institute to develop an immunotherapy targeting cancer cells with mutations in the BRAF gene.
More from Ovarian Cancer News Today:
BioNewsFeeds 09/18/2019 11:12
IMV announced that it has joined with the Wistar Institute to develop an immunotherapy targeting cancer cells with mutations in the BRAF gene.
More from BioNewsFeeds:
Mouse studies Now bacterial immunotherapy may soon return to the oncology clinic, says a review of these mouse studies.
More from Medical Xpress - Immunology news:
ESMO News (EU) 09/18/2019 09:03
The other first author of the study, Dr Mirte Muller, a PhD student in the department of thoracic oncology at The Netherlands Cancer Institute, said: “We found that before the start of treatment with immunotherapy, the eNose analysis of exhaled breath from the patients with non-small cell lung cancer could distinguish between responders and non-responders with ...
More from ESMO News (EU):
Today, the American Association for Cancer Research (AACR) released its ninth annual Cancer Progress Report.
More from American Association for Cancer Research (AACR): 09/18/2019 07:52
In our preclinical studies, we made several genes called a chimeric antigen receptor (CAR), from an antibody called GC33 that recognizes glypican-3, a protein found on almost all hepatocellular carcinoma cells and hepatoblastoma cells (GPC3-CAR.
More from
This phase II prospective trial explored the benefits of treating one cancerous lesion with stereotactic body radiotherapy (SBRT) in patients with NSCLC whose cancer had continued to spread after treatment with pembrolizumab, a type of immunotherapy.
More from Imaging Technology News:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications